Incyte Corporation (NASDAQ:INCY) insider Paul Trower sold 3,000 shares of Incyte Corporation stock in a transaction on Friday, August 4th. The shares were sold at an average price of $125.25, for a total value of $375,750.00. Following the sale, the insider now directly owns 11,853 shares of the company’s stock, valued at approximately $1,484,588.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Paul Trower also recently made the following trade(s):

  • On Wednesday, July 5th, Paul Trower sold 3,000 shares of Incyte Corporation stock. The shares were sold at an average price of $126.18, for a total value of $378,540.00.
  • On Monday, June 5th, Paul Trower sold 3,000 shares of Incyte Corporation stock. The stock was sold at an average price of $132.50, for a total value of $397,500.00.

Incyte Corporation (NASDAQ INCY) opened at 130.70 on Wednesday. The company’s 50-day moving average price is $130.84 and its 200-day moving average price is $128.99. The stock’s market cap is $26.89 billion. Incyte Corporation has a one year low of $75.52 and a one year high of $153.15.

Incyte Corporation (NASDAQ:INCY) last announced its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The firm had revenue of $326.40 million during the quarter, compared to the consensus estimate of $318.45 million. Incyte Corporation had a negative return on equity of 21.57% and a negative net margin of 11.77%. The firm’s revenue for the quarter was up 32.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.18 EPS. Analysts forecast that Incyte Corporation will post ($0.85) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Incyte Corporation (NASDAQ:INCY) Insider Sells 3,000 Shares of Stock” was originally published by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/08/09/insider-selling-incyte-corporation-nasdaqincy-insider-sells-3000-shares-of-stock.html.

Several equities research analysts have issued reports on INCY shares. Piper Jaffray Companies reaffirmed a “neutral” rating and set a $124.00 price target on shares of Incyte Corporation in a research note on Monday, April 17th. Jefferies Group LLC reaffirmed a “buy” rating and set a $148.00 price target (down previously from $165.00) on shares of Incyte Corporation in a research note on Monday, April 17th. Raymond James Financial, Inc. reaffirmed a “hold” rating on shares of Incyte Corporation in a research note on Monday, April 17th. Vetr raised Incyte Corporation from a “buy” rating to a “strong-buy” rating and set a $151.58 price target for the company in a research note on Monday, April 17th. Finally, Goldman Sachs Group, Inc. (The) dropped their price target on Incyte Corporation from $149.00 to $136.00 and set a “buy” rating for the company in a research note on Tuesday, April 18th. Seven analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $140.39.

Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Incyte Corporation by 22.7% in the first quarter. Vanguard Group Inc. now owns 15,415,857 shares of the biopharmaceutical company’s stock worth $2,060,638,000 after buying an additional 2,847,907 shares during the period. State Street Corp raised its position in shares of Incyte Corporation by 110.7% in the first quarter. State Street Corp now owns 7,581,684 shares of the biopharmaceutical company’s stock worth $1,013,437,000 after buying an additional 3,983,207 shares during the period. FMR LLC raised its position in shares of Incyte Corporation by 8.0% in the first quarter. FMR LLC now owns 2,980,864 shares of the biopharmaceutical company’s stock worth $398,452,000 after buying an additional 219,923 shares during the period. Geode Capital Management LLC raised its position in shares of Incyte Corporation by 42.0% in the first quarter. Geode Capital Management LLC now owns 1,780,064 shares of the biopharmaceutical company’s stock worth $237,618,000 after buying an additional 526,163 shares during the period. Finally, UBS Asset Management Americas Inc. raised its position in shares of Incyte Corporation by 23.9% in the first quarter. UBS Asset Management Americas Inc. now owns 1,477,461 shares of the biopharmaceutical company’s stock worth $197,492,000 after buying an additional 284,796 shares during the period. 91.73% of the stock is currently owned by institutional investors and hedge funds.

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Insider Buying and Selling by Quarter for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.